Reuters logo
BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib
September 5, 2017 / 8:17 PM / 3 months ago

BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib

Sept 5 (Reuters) - Mei Pharma Inc

* Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor

* Mei Pharma Inc - ‍Presage will receive near-term payments of $2.9 million​

* Mei Pharma Inc - ‍Presage will also receive mid-single-digit tiered royalties on net sales of any product successfully developed​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below